Display options
Cite
Shofer S, Beyea M, Li S, et al. Feasibility of using an epigenetic marker of risk for lung cancer, methylation of p16, to promote smoking cessation among US veterans. BMJ Open Respir Res. 2014;1(1):e000032doi: 10.1136/bmjresp-2014-000032.
Shofer, S., Beyea, M., Li, S., Bastian, L. A., Wahidi, M. M., Kelley, M., & Lipkus, I. M. (2014). Feasibility of using an epigenetic marker of risk for lung cancer, methylation of p16, to promote smoking cessation among US veterans. BMJ open respiratory research, 1(1), e000032. https://doi.org/10.1136/bmjresp-2014-000032
Shofer, Scott, et al. "Feasibility of using an epigenetic marker of risk for lung cancer, methylation of p16, to promote smoking cessation among US veterans." BMJ open respiratory research vol. 1,1 (2014): e000032. doi: https://doi.org/10.1136/bmjresp-2014-000032
Shofer S, Beyea M, Li S, Bastian LA, Wahidi MM, Kelley M, Lipkus IM. Feasibility of using an epigenetic marker of risk for lung cancer, methylation of p16, to promote smoking cessation among US veterans. BMJ Open Respir Res. 2014 Jun 28;1(1):e000032. doi: 10.1136/bmjresp-2014-000032. eCollection 2014. PMID: 25478181; PMCID: PMC4212704.
Copy Download .nbib Format: NLM
Share it on

BMJ Open Respir Res. 2014 Jun 28;1(1):e000032. doi: 10.1136/bmjresp-2014-000032. eCollection 2014.

Feasibility of using an epigenetic marker of risk for lung cancer, methylation of p16, to promote smoking cessation among US veterans.

BMJ open respiratory research

Scott Shofer, Matthew Beyea, Sufeng Li, Lori A Bastian, Momen M Wahidi, Michael Kelley, Isaac M Lipkus

Affiliations

  1. Pulmonary Section , Durham Veteran Affairs Medical Center , Durham, North Carolina , USA ; Division of Pulmonary, Allergy, and Critical Care , Duke University Medical Center , Durham, North Carolina , USA.
  2. Pulmonx, Inc. , Redwood City, California , USA.
  3. Division of Hematology/Oncology , Duke University Medical Center , Durham, North Carolina , USA.
  4. Department of Internal Medicine , Veteran Administration Connecticut Healthcare System , West Haven, Connecticut , USA ; Department of Internal Medicine , University of Connecticut Health Center , Farmington, Connecticut , USA.
  5. Division of Pulmonary, Allergy, and Critical Care , Duke University Medical Center , Durham, North Carolina , USA.
  6. Division of Hematology/Oncology , Duke University Medical Center , Durham, North Carolina , USA ; Hematology and Oncology Section, Durham Veterans Affairs Medical Center, Durham, North Carolina , USA.
  7. Duke University School of Nursing , Durham, North Carolina , USA.

PMID: 25478181 PMCID: PMC4212704 DOI: 10.1136/bmjresp-2014-000032

Abstract

INTRODUCTION: Providing smokers feedback using epigenetic markers of lung cancer risk has yet to be tested as a strategy to motivate smoking cessation. Epigenetic modification of Rb-p16 (p16) due to tobacco exposure is associated with increased risk of developing lung cancer. This study examined the acceptance of testing for methylated p16 and the understanding of test results in smokers at risk for development of lung cancer.

METHODS: Thirty-five current smokers with airways obstruction viewed an educational presentation regarding p16 function followed by testing for the presence of methylated p16 in sputum. Participants were offered smoking cessation assistance and asked to complete surveys at the time of enrolment regarding their understanding of the educational material, perception of risk associated with smoking and desire to quit. Participants were notified of their test result and follow-up surveys were administered 2 and 10 weeks after notification of their test result.

RESULTS: Twenty per cent of participants had methylated p16. Participants showed high degree of understanding of educational materials regarding the function and risk associated with p16 methylation. Sixty-seven per cent and 57% of participants with low-risk and high-risk test results, respectively, reported that the information was more likely to motivate them to quit smoking. Smoking cessation rates were similar between methylated and non-methylated participants.

CONCLUSIONS: Testing for an epigenetic marker of lung cancer risk is accepted and understood by active smokers. A low-risk test result does not decrease motivation to stop smoking.

TRIAL REGISTRATION NUMBER: NCT01038492.

Keywords: Lung Cancer; Tobacco and the lung

References

  1. Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):1953-61 - PubMed
  2. Neoplasia. 2006 Jan;8(1):46-51 - PubMed
  3. Cell. 2007 Feb 23;128(4):683-92 - PubMed
  4. Nat Rev Cancer. 2006 Feb;6(2):107-16 - PubMed
  5. Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11891-6 - PubMed
  6. BMJ. 2008 Mar 15;336(7644):598-600 - PubMed
  7. Cochrane Database Syst Rev. 2012 Dec 12;12:CD004705 - PubMed
  8. Cancer Res. 2006 Feb 1;66(3):1371-5 - PubMed
  9. Cancer Epidemiol. 2010 Feb;34(1):96-100 - PubMed
  10. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD004705 - PubMed
  11. Health Psychol. 1997 Jan;16(1):87-99 - PubMed
  12. Cancer Res. 2001 Apr 15;61(8):3419-24 - PubMed
  13. Nat Rev Genet. 2006 Jan;7(1):21-33 - PubMed
  14. J Health Commun. 2000 Jul-Sep;5(3):229-41 - PubMed
  15. Cancer Res. 1996 Aug 15;56(16):3655-8 - PubMed
  16. JAMA. 2014 Jan 8;311(2):197-9 - PubMed
  17. Cancer Res. 2006 Mar 15;66(6):3338-44 - PubMed
  18. Int J Cancer. 2003 Jan 10;103(2):153-60 - PubMed
  19. CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29 - PubMed
  20. Addict Behav. 1997 Nov-Dec;22(6):741-51 - PubMed
  21. Cancer Res. 2002 Apr 15;62(8):2370-7 - PubMed
  22. J Natl Cancer Inst. 1999 Apr 21;91(8):675-90 - PubMed

Publication Types

Grant support